

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

29 April 2021

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

R&D Tax Incentive


Biotron Limited (ASX: BIT) is pleased to announce that it has received an R&D Tax Incentive refund of \$1,411,944 R&D Tax Incentive refund for the 2019/20 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The incentive refund results from expenditure on Biotron's antiviral drug development programs.

Biotron's Managing Director, Dr Michelle Miller commented: "Whilst Biotron is fully funded for its current activities, this R&D cash rebate will strengthen the Company's cash position and support commercialisation activities."

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn10758

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and promising preclinical programs for SARS-CoV-2 and Hepatitis B Virus. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

This announcement has been approved by the Company's Managing Director.